- Molecular NameVigabatrin
- Synonym4-Amino-5-hexenoic acid; 4-Aminohexenoic acid; gamma-Vinyl GABA; GVG; Sabril (TN); Vigabatrin [USAN:BAN:INN]; Vigabatrina [Spanish]; Vigabatrine; Vigabatrine [French]; Vigabatrinum [Latin]
- Weight129.159
- Drugbank_IDDB01080
- ACS_NO60643-86-9
- Show 3D model
- LogP (experiment)-2.16
- LogP (predicted, AB/LogP v2.0)-1.92
- pka4.02, 9.72
- LogD (pH=7, predicted)-1.93
- Solubility (experiment)332 mg/ml
- LogS (predicted, ACD/Labs)(ph=7)-0.48
- LogSw (predicted, AB/LogsW2.0)392.72
- Sw (mg/ml) (predicted, ACD/Labs)42.9
- No.of HBond Donors3
- No.of HBond Acceptors3
- No.of Rotatable Bonds4
- TPSA63.32
- StatusFDA approved
- AdministrationN/A
- PharmacologyAn antiepileptic drug that inhibits the catabolism of gamma-Aminobutyric acid (GABA) by irreversibly inhibiting GABA transaminase.
- Absorption_valueN/A
- Absorption (description)Rapidly absorbed following oral administration. Food may slightly decrease the rate, but not the extent, of absorption.
- Caco_2N/A
- Bioavailability100.0
- Protein binding0.0
- Volume of distribution (VD)0.8 L/kg
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmAlmost no metabolic transformation occurs
- Half life5~8 h
- ExcretionRenal
- Urinary ExcretionN/A
- CleranceN/A
- ToxicityN/A
- LD50 (rat)N/A
- LD50 (mouse)N/A